# EDGAR Filing Document

**Accession Number:** 0001446159
**File Stem:** 0001171843-23-001661
**Filing Date:** 2023-3
**Character Count:** 10337
**Document Hash:** c0c32acdbc5d2a13e588fbc28e86bb73
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-23-001661.hdr.sgml**: 20230314

**ACCESSION NUMBER**: 0001171843-23-001661

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230314

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230314

**DATE AS OF CHANGE**: 20230314

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Predictive Oncology Inc.
- **CENTRAL INDEX KEY:** 0001446159
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **IRS NUMBER:** 331007393
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36790
- **FILM NUMBER:** 23729271

**BUSINESS ADDRESS:**
- **STREET 1:** 2915 COMMERS DRIVE,
- **STREET 2:** SUITE 900
- **CITY:** EAGAN
- **STATE:** MN
- **ZIP:** 55121
- **BUSINESS PHONE:** 651-389-4800

**MAIL ADDRESS:**
- **STREET 1:** 2915 COMMERS DRIVE,
- **STREET 2:** SUITE 900
- **CITY:** EAGAN
- **STATE:** MN
- **ZIP:** 55121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Precision Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20180314

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Precision Therapeutic Inc.
- **DATE OF NAME CHANGE:** 20180208

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Skyline Medical Inc.
- **DATE OF NAME CHANGE:** 20130807

?xml version="1.0" encoding="utf-8"?Form 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

### Washington, D.C. 20549
_________________

### FORM 8-K
_________________

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): March 14, 2023
_______________________________

#### Predictive Oncology Inc.
(Exact name of registrant as specified in its charter)

_______________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36790** | **33-1007393** |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

#### 2915 Commers Drive, Suite 900

#### Eagan, Minnesota 55121
(Address of Principal Executive Offices) (Zip Code)

(651) 389-4800

(Registrant's telephone number, including area code)

#### Not Applicable
(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, $0.01 par value | POAI | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01. Regulation FD Disclosure.**

On March 14, 2023, Predictive Oncology Inc. issued a press release disclosing that it has engaged LifeSci Advisors, a leading New York-based investor relations consultancy serving life science, to implement a comprehensive IR program. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 7.01, including Exhibit 99.1, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| [99.1](exh_991.htm) | [Press Release dated March 14, 2023](exh_991.htm) |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL) |

---

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Predictive Oncology Inc.** | **Predictive Oncology Inc.** |
| Date: March 14, 2023 | By: | <u>/s/ Bob Myers&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  |  | Bob Myers |
|  |  | Chief Financial Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**Predictive Oncology Engages LifeSci Advisors as Strategic Investor Relations Partner**

**Comprehensive, multi-faceted IR program to focus on raising awareness of Predictive Oncology and its portfolio of unique, proprietary assets capable of accelerating oncologic drug discovery and enabling drug development** 

EAGAN, Minn., March 14, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology **(Nasdaq: POAI)**, a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, today announced that it has engaged LifeSci Advisors, a leading New York-based investor relations (IR) consultancy serving life science companies, to implement a comprehensive IR program that will include, among other key activities, targeting of and outreach to leading analysts and institutional investors, bank conference targeting, non-deal roadshows, corporate communications, and Key Opinion Leader (KOL) events focused on AI and machine learning-assisted drug discovery.

"Simply put, since assuming the role of CEO last November, I have been blown away by the untapped potential of our assets and capabilities, including our artificial intelligence drug discovery engine, PEDAL™, that we can leverage against our extensive biobank of more than 150,000 tumor samples and 200,000 pathology slides to accelerate and de-risk drug discovery on behalf of academic institution and drug development partners," stated Raymond F. Vennare, Chief Executive Officer of Predictive Oncology.

"With the global AI-assisted drug development market currently at $1.1 billion and growing at nearly 30% per year, we are indeed in the right place at the right time. I believe the time is now to aggressively raise awareness of our company among influential life sciences analysts, top tier institutional health care investors, and other critical participants in the Wall Street health care ecosystem. LifeSci Advisors is the largest integrated investor relations firm in healthcare and the life sciences with global operations across North America, Europe, and Israel. Given its many case studies demonstrating the success of its programs, and its highly specialized team with experience working with companies across the entire drug development spectrum, I believe LifeSci is the perfect partner for us at this time and I look forward to a mutually successful relationship."

**About Predictive Oncology Inc.** As a science-driven company on the leading edge of oncology drug discovery, Predictive Oncology (NASDAQ: POAI) offers an unrivaled suite of solutions for the biopharma industry. Through the integration of scientific rigor and machine learning, the company has developed the ability to advance molecules into medicine more confidently by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the world's largest privately held biobank of over 150K tumor samples. Predictive Oncology's solutions additionally include tumor models, biologics development, formulation design, a GMP facility, a CLIA laboratory and substantial scientific domain expertise.

**Forward-Looking Statements:** Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "would," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading "Risk Factors" in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

**Investor Relations Contact:** Tim McCarthy

LifeSci Advisors, LLC.

tim@lifesciadvisors.com